Skip to main content

Table 2 Serostatus of the study population

From: Alterations in pathogen-specific cellular and humoral immunity associated with acute peripheral facial palsy of infectious origin

n (%)

Immunoglobulin levels

p-value*

Negative

Intermediate

Positive

VZV

IgG

Controls

0 (0)

0 (0)

23 (100)

p = 0.551

PFP

3 (5.5)

1 (1.8)

51 (92.7)

IgA

Controls

18 (78.3)

3 (13.0)

2 (8.7)

p = 0.078

PFP

31 (56.4)

2 (3.6)

22 (40.0)

HSV

IgG

Controls

11 (47.8)

0 (0)

12 (52.2)

p = 0.0003

PFP

5 (9.1)

0 (0)

50 (90.9)

IgA

Controls

13 (56.5)

2 (8.7)

8 (34.8)

p = 0.133

PFP

20 (36.4)

9 (16.4)

26 (47.3)

IgM

Controls

19 (82.6)

3 (13.0)

1 (4.3)

p = 0.470

PFP

49 (89.1)

4 (7.3)

2 (3.6)

Borrelia

IgG

Controls

19 (82.6)

2 (8.7)

2 (8.7)

p > 0.9999

PFP

47 (85.5)

2 (3.6)

6 (10.9)

IgM

Controls

23 (100)

0 (0)

0 (0)

p > 0.9999

PFP

53 (96.4)

0 (0)

2 (3.6)

CMV

IgG

Controls

12 (52.2)

0 (0)

11 (47.8)

p = 0.626

PFP

25 (45.5)

0 (0)

30 (54.5)

  1. *p-values were calculated by Fisher’s exact test, where patients with intermediate and positive results were compared with negative results
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094